TRADD抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using TRADD mouse mAb (green) and negative control (red).    

  
  

TRADD (Tumor Necrosis Factor Receptor Type 1-Associated Death Domain Protein) is a critical adaptor protein involved in mediating signaling pathways triggered by tumor necrosis factor receptor 1 (TNFR1). Discovered in the mid-1990s, TRADD plays a dual role in cell survival and apoptosis by recruiting downstream effectors like FADD (FAS-associated death domain) and TRAF2 (TNF receptor-associated factor 2). It acts as a central hub, linking TNFR1 activation to both pro-inflammatory NF-κB signaling and caspase-dependent apoptotic pathways, depending on cellular context and external stimuli. Dysregulation of TRADD has been implicated in cancer, autoimmune disorders, and inflammatory diseases.

TRADD antibodies are essential tools for studying these pathways. They enable the detection and quantification of TRADD expression in cells or tissues via techniques like Western blotting, immunohistochemistry, and flow cytometry. Researchers also use TRADD-specific antibodies for co-immunoprecipitation assays to investigate protein-protein interactions within TNFR1 signaling complexes. High-quality TRADD antibodies are validated for specificity, often using knockout cell lines as controls, to ensure accurate results. These reagents are vital for elucidating TRADD's role in disease mechanisms, drug response studies, and exploring therapeutic targets within the TNF signaling network. Both monoclonal and polyclonal TRADD antibodies are available, each offering distinct advantages in experimental design.